Abstract: The present application generally relates to a method to treat a patient with a bacterial infection caused by Clostridium difficile. Particularly the method compromises the step of administering a therapeutically effective amount of diiodohydroxyquinoline, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.

Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

Abstract: A method to treat a patient with a Clostridium difficile infection comprising administering a therapeutically effective amount of diiodohydroxyquinoline, with or without one or more anti-infective agents.

Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

Abstract: A method for the determination of antibiotic susceptibility through stimulated Raman scattering microscopy is disclosed. The method utilizes a imaging apparatus adapted to collect a laser signal through a sample having a bacteria for imaging the metabolism of the sample. The sample can be manipulated with an antibiotic for imaging to determine the susceptibility of a bacteria to the provided antibiotic.

Abstract: The invention described generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as an antibiotic against Neisseria gonorrhea bacteria and methods for treating those sexually transmitted infection diseases in mammals using the described carbonic anhydrase inhibitors having a formula (I), or a pharmaceutical formulation thereof, alone or together with one or more other antibiotics.

Abstract: The invention described herein generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as a narrow spectrum antibiotics against drug resistant bacteria and methods for treating those infection diseases in mammals using the described carbonic anhydrase inhibitors or a pharmaceutical formulation thereof.

Abstract: A method for the determination of antibiotic susceptibility through stimulated Raman scattering microscopy is disclosed. The method utilizes a imaging apparatus adapted to collect a laser signal through a sample having a bacteria for imaging the metabolism of the sample. The sample can be manipulated with an antibiotic for imaging to determine the susceptibility of a bacteria to the provided antibiotic.

Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

Abstract: The present invention generally relates to compounds, composition matters, and methods for the treatment of a patient with an infection caused by microorganisms, including bacterial, viral, and fungal infections. In particular, this disclosure relates to safe, highly potent and fast acting antimicrobial agents ?-methylene and ?-aminomethyl lactones, lactams, iminolactones, and iminolactams, thiolactones, thionolactones, thiolactams, and thionolactams having a formula of I, II, III, or IV, for the treatment of viral and bacterial infections, especially for infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

Abstract: The present invention provides aryl isonitrile compounds that have antibacterial properties. More specifically, the aryl isonitrile compounds of the present invention are potent inhibitors of drug resistant strains of Staphylococcus aureus.

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) possesses array of strategies to evade antibiotics through mutational inactivation, hiding inside host immune cells or concealing inside the biofilm in a sessile form. We report a drug-free approach to eradicate MRSA through blue-light bleaching of staphyloxanthin (STX), an anti-oxidative carotenoid residing inside the cell membrane of S. aureus. The photobleaching process, uncovered through a transient absorption imaging study and quantitated by mass spectrometry, decomposes STX and sensitizes MRSA to reactive oxygen species attack. Consequently, photobleaching using low-level blue light exhibits high-level synergy when combined with low-concentration of hydrogen peroxide. Antimicrobial effectiveness of this synergistic therapy is validated in MRSA culture, MRSA-infected macrophage cells, biofilm, and a mouse wound infection model. Collectively, these findings highlight broad applications of STX photobleaching for MRSA-infected diseases.

Abstract: The present application generally relates to a method to treat a patient with a bacterial infection caused by Clostridium difficile. Particularly the method compromises the step of administering a therapeutically effective amount of diiodohydroxyquinoline, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.

Abstract: The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

Abstract: The present disclosure relates to novel antibacterial cell-penetrating peptides and derivatives, and methods to make and use the novel antibacterial cell-penetrating peptides and derivatives. The novel antibacterial cell-penetrating peptides of the present invention with shorter linker between a pyrrolidine ring and a guanidine group provide unexpectedly higher potency against a broader scope of bacterial.

Abstract: Confronted with the rapid evolution and dissemination of antibiotic resistance, there is an urgent need to develop alternative treatment strategies for drug-resistant S. aureus, especially for methicillin-resistant S. aureus (MRSA). We report a photonic approach to eradicate MRSA through blue-light photolysis of staphyloxanthin (STX), an anti-oxidative carotenoid acting as the constituent lipid of the functional membrane microdomains of S. aureus. Our transient absorption imaging study and mass spectrometry unveil the photolysis process of STX. After effective STX photolysis by pulsed laser, cell membranes are found severely disorganized and malfunctioned to defense antibiotics, as unveiled by membrane permeabilization, membrane fluidification, and detachment of membrane protein, PBP2a.

Abstract: A method for the determination of antibiotic susceptibility through stimulated Raman scattering microscopy is disclosed. The method utilizes a imaging apparatus adapted to collect a laser signal through a sample having a bacteria for imaging the metabolism of the sample. The sample can be manipulated with an antibiotic for imaging to determine the susceptibility of a bacteria to the provided antibiotic.

Abstract: The present disclosure relates to novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide, and methods to make and use the novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide.

Abstract: The present disclosure relates to novel antibacterial cell-penetrating peptides and derivatives, and methods to make and use the novel antibacterial cell-penetrating peptides and derivatives. The novel antibacterial cell-penetrating peptides of the present invention with shorter linker between a pyrrolidine ring and a guanidine group provide unexpectedly higher potency against a broader scope of bacterial.